miR-124-3p relieves allergic rhinitis by inhibiting dipeptidyl peptidase-4

Shitao Zhang1, Dong Dong1, Yuan Zhang1

  • 1Department of Rhinology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.

Insights

MicroRNA-124-3p (miR-124-3p) is downregulated in allergic rhinitis (AR). Upregulating miR-124-3p reduces AR inflammation and cell injury by targeting dipeptidyl peptidase-4 (DPP4).

Area of Science:

  • Immunology
  • Molecular Biology
  • Cell Biology

Background:

  • MicroRNA-124-3p (miR-124-3p) and dipeptidyl peptidase-4 (DPP4) play roles in inflammation.
  • Allergic rhinitis (AR) is an inflammatory condition affecting the nasal mucosa.

Purpose of the Study:

  • To investigate the role of the miR-124-3p/DPP4 axis in AR.
  • To explore miR-124-3p as a potential therapeutic target for AR.

Main Methods:

  • Established mouse and human nasal epithelial cell (HNEpC) models of AR.
  • Assessed AR progression via clinical symptoms, histology (HE, TUNEL), and inflammatory markers (TNF-α, IL-6, GM-CSF, eotaxin, MUC5AC) using ELISA and qRT-PCR.
  • Evaluated apoptosis via flow cytometry and protein expression (DPP4, caspase-3) via western blotting.

Main Results:

  • miR-124-3p was downregulated in AR nasal mucosa.
  • Upregulating miR-124-3p alleviated AR symptoms, reduced inflammation, eosinophil infiltration, and apoptosis in nasal mucosa.
  • miR-124-3p targeted DPP4, influencing AR inflammation and cell injury.

Conclusions:

  • The miR-124-3p/DPP4 axis is implicated in AR pathogenesis.
  • Modulating miR-124-3p offers a potential therapeutic strategy for allergic rhinitis.

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
292
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
681
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
709
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
475
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
671
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
658